Eikon Therapeutics

Eikon Therapeutics is a biopharmaceutical company (Nasdaq: EIKN) founded in 2019 and headquartered in Millbrae, California, with additional offices in New York and Jersey City. Eikon built a proprietary drug-discovery platform around single-molecule live-cell imaging, applying super-resolution fluorescence microscopy and high-throughput single-molecule tracking to observe how proteins and drug targets move and interact inside living cells in real time. The technology descends from co-founder Eric Betzig's Nobel Prize-winning work in super-resolution microscopy, and the company is led by former Merck R&D chief Roger Perlmutter. Eikon uses these measurements to discover and develop novel therapeutics across oncology and other disease areas. This profile was surfaced as a portfolio company of Lux Capital and enriched by the API Evangelist pipeline; Eikon publishes a corporate and investor web presence but no public developer API, SDK, or machine-readable API surface at this time.

Eikon Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotech, Biopharmaceutical, Drug Discovery, and Live-Cell Imaging.

Eikon Therapeutics’ developer surface includes product news and 8 more developer resources.

🌐 Visit website 📡 Source on GitHub

6.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

CompanyBiotechBiopharmaceuticalDrug DiscoveryLive-Cell ImagingSuper-Resolution MicroscopyOncologyLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 6.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 1.8 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.9 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/eikon-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 6

The organization behind the API

Website

About

News

Careers

Investors

LinkedIn

Source (apis.yml)

aid: eikon-therapeutics
name: Eikon Therapeutics
description: 'Eikon Therapeutics is a biopharmaceutical company (Nasdaq: EIKN) founded in 2019 and headquartered in Millbrae,
  California, with additional offices in New York and Jersey City. Eikon built a proprietary drug-discovery platform around
  single-molecule live-cell imaging, applying super-resolution fluorescence microscopy and high-throughput single-molecule
  tracking to observe how proteins and drug targets move and interact inside living cells in real time. The technology descends
  from co-founder Eric Betzig''s Nobel Prize-winning work in super-resolution microscopy, and the company is led by former
  Merck R&D chief Roger Perlmutter. Eikon uses these measurements to discover and develop novel therapeutics across oncology
  and other disease areas. This profile was surfaced as a portfolio company of Lux Capital and enriched by the API Evangelist
  pipeline; Eikon publishes a corporate and investor web presence but no public developer API, SDK, or machine-readable API
  surface at this time.'
url: https://raw.githubusercontent.com/api-evangelist/eikon-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- lux-capital
x-tier: stub
x-tier-reason: portfolio-lead
x-ticker: EIKN
x-hq: Millbrae, California, United States
x-founded: '2019'
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.eikontx.com/wp-content/uploads/2023/12/logo-eikon.png
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotech
- Biopharmaceutical
- Drug Discovery
- Live-Cell Imaging
- Super-Resolution Microscopy
- Oncology
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/eikon-therapeutics-domain-security.yml
- type: Website
  url: https://www.eikontx.com
- type: About
  url: https://www.eikontx.com/about-us/
- type: News
  url: https://www.eikontx.com/news/
- type: Careers
  url: https://www.eikontx.com/careers/
- type: Contact
  url: https://www.eikontx.com/contact/
- type: Investors
  url: https://investors.eikontx.com/
- type: PrivacyPolicy
  url: https://www.eikontx.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/eikon-therapeutics-inc/
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence